In KRAS-mutant colorectal cancer, the addition of ferroptosis inducers to cetuximab (an anti-EGFR monoclonal antibody) overcomes the limited efficacy of cetuximab-based chemotherapy imposed by KRAS mutation, effectively suppressing tumor growth and lymph node metastasis (38). This evidence concerns the gene KRAS and neoplasm.